It was January 2013, freezing cold, and I was back at my desk in the City with a box of tissues and a mug of Lemsip on the go ...

PALI-2108 is the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

The ulcerative colitis market is experiencing steady growth driven by rising disease prevalence and increasing diagnosis rates worldwide. Expanding adoption of advanced biologics, small-molecule ...

Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight The ulcerative colitis market is ...

Ulcerative Colitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ...

Lymphocytic colitis is a bowel condition characterized by chronic, watery diarrhea and the buildup of white blood cells in your gut. It is most common in older adults. Lymphocytic colitis is a rare ...

As mentioned, Crohn’s colitis is a subtype of Crohn’s disease that only affects the colon. “We typically label Crohn’s based on what part of the gastrointestinal tract it affects,” says Sara ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...